DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases , with late-stage development programs including REMOXY ( R ) , POSIDUR ( TM ) , ELADUR ( TM ) , and TRANSDUR ( TM ) -Sufentanil . DURECT 's proprietary oral , transdermal and injectable depot delivery technologies may enable new indications and superior clinical / commercial attributes such as abuse deterrence , improved convenience , compliance , efficacy and safety for small molecule and biologic drugs . For more information , please visit www.durect.com.